|
| SELEXIPAG interMediate Basic information |
Product Name: | SELEXIPAG interMediate | Synonyms: | SELEXIPAG interMediate;4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;Selexipag intermediates;1-Butanol, 4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]-;1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-;4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]-1-butanol;-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butan-1-ol | CAS: | 475086-75-0 | MF: | C23H27N3O | MW: | 361.48 | EINECS: | 813-799-3 | Product Categories: | selexipag;non-prostanoid prostacyclin (PGI2) receptor agonist | Mol File: | 475086-75-0.mol | |
| SELEXIPAG interMediate Chemical Properties |
Melting point | 68 - 71°C | Boiling point | 514.4±50.0 °C(Predicted) | density | 1.112±0.06 g/cm3(Predicted) | storage temp. | Sealed in dry,Room Temperature | solubility | Chloroform (Slightly), DMSO (Slightly) | pka | 15.05±0.10(Predicted) | form | Solid | color | Pale Yellow to Light Yellow |
| SELEXIPAG interMediate Usage And Synthesis |
Uses | 4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol is a diphenylpyrazine derivative which belongs to a class of prostacyclin receptor agonists. It is an impurity of Selexipag (S253150) that is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans. | Application | Selexipag interMediate is a synthetic organic compound that is used as an intermediate in the synthesis of oxychloride. It is an oxychloride with a nucleophilic substitution reaction. The reaction proceeds selectively at the phosphorus atom and gives high yield. The reactivity of 4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butan-1-ol is enhanced by the use of n butanol, which also acts as a solvent for the reaction. The product can be purified by filtration or recrystallization from hexane with piperazine as a reagent. |
| SELEXIPAG interMediate Preparation Products And Raw materials |
|